Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Analgesia, ObstetricalPostpartum HemorrhageOpioid UseNonsteroidals (NSAIDs)ToxicityCoagulation Defect; PostpartumPostoperative PainKetorolac Adverse ReactionBlood Loss, Postoperative
Interventions
DRUG

Ketorolac

Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.

DRUG

Placebo

Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.

Trial Locations (1)

44106

University Hospitals Case Medical Center, Cleveland

All Listed Sponsors
lead

University Hospitals Cleveland Medical Center

OTHER

NCT02509312 - Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery | Biotech Hunter | Biotech Hunter